$GYRE
GYRE THERAPEUTICS, INC.

2019 Q3 Form 10-Q Financial Statement

#000156459019041706 Filed on November 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q3 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.270M $2.770M $3.230M
YoY Change 18.05% 15.9% 21.89%
% of Gross Profit
Research & Development $9.927M $5.575M $3.889M
YoY Change 78.06% 46.33% 14.35%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $100.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $13.20M $8.345M $7.114M
YoY Change 58.12% 34.6% 109.17%
Operating Profit -$13.20M -$8.345M -$7.114M
YoY Change 58.12% 19.68%
Interest Expense $489.0K $652.0K $602.0K
YoY Change -25.0% 667.06% 1035.85%
% of Operating Profit
Other Income/Expense, Net $0.00 -$1.000K $30.00K
YoY Change -100.0% -101.18% -55.22%
Pretax Income -$12.71M -$7.690M -$6.480M
YoY Change 65.28% 32.82% 10.2%
Income Tax
% Of Pretax Income
Net Earnings -$12.71M -$7.694M -$6.482M
YoY Change 65.14% 32.88% 10.24%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.057M -$644.1K -$542.7K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.00M $129.2M $136.1M
YoY Change -34.21% 369.82% 320.06%
Cash & Equivalents $23.02M $36.00M $46.53M
Short-Term Investments $61.90M $93.20M $89.60M
Other Short-Term Assets $4.200M $3.600M $2.900M
YoY Change 16.67% -44.62% -57.35%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $89.10M $132.8M $139.0M
YoY Change -32.91% 289.44% 253.63%
LONG-TERM ASSETS
Property, Plant & Equipment $339.0K $300.0K $300.0K
YoY Change 13.0% 0.0% -16.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $352.0K $274.0K
YoY Change -14.77%
Total Long-Term Assets $2.692M $600.0K $523.0K
YoY Change 348.67% 100.0% 58.48%
TOTAL ASSETS
Total Short-Term Assets $89.10M $132.8M $139.0M
Total Long-Term Assets $2.692M $600.0K $523.0K
Total Assets $91.79M $133.4M $139.5M
YoY Change -31.19% 287.79% 252.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.123M $400.0K $100.0K
YoY Change 430.75% -73.33% -80.04%
Accrued Expenses $7.000M $2.900M $2.300M
YoY Change 141.38% 45.0% 9.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.077M $3.300M $2.400M
YoY Change 175.06% -65.26% -74.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.400M $200.0K $100.0K
YoY Change 600.0%
Total Long-Term Liabilities $1.400M $200.0K $100.0K
YoY Change 600.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.077M $3.300M $2.400M
Total Long-Term Liabilities $1.400M $200.0K $100.0K
Total Liabilities $10.52M $3.465M $2.600M
YoY Change 203.61% -63.53% -71.99%
SHAREHOLDERS EQUITY
Retained Earnings -$244.9M -$192.5M
YoY Change 27.22%
Common Stock $12.00K $12.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $81.27M $130.0M $137.0M
YoY Change
Total Liabilities & Shareholders Equity $91.79M $133.4M $139.5M
YoY Change -31.2% 287.84% 252.01%

Cashflow Statement

Concept 2019 Q3 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$12.71M -$7.694M -$6.482M
YoY Change 65.14% 32.88% 10.24%
Depreciation, Depletion And Amortization $0.00 $0.00 $100.0K
YoY Change 0.0%
Cash From Operating Activities -$9.100M -$7.000M -$7.400M
YoY Change 30.0% 42.86% 68.18%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $14.60M -$3.700M -$72.60M
YoY Change -494.59% -77.58%
Cash From Investing Activities $14.70M -$3.700M -$72.60M
YoY Change -497.3% -77.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K 0.000 100.0K
YoY Change -100.0% -99.35%
NET CHANGE
Cash From Operating Activities -9.100M -7.000M -7.400M
Cash From Investing Activities 14.70M -3.700M -72.60M
Cash From Financing Activities 100.0K 0.000 100.0K
Net Change In Cash 5.700M -10.70M -79.90M
YoY Change -153.27% -50.69% -826.36%
FREE CASH FLOW
Cash From Operating Activities -$9.100M -$7.000M -$7.400M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$9.100M -$7.000M -$7.400M
YoY Change 30.0% 42.86% 68.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M17D
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
88914000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3268000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2770000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-5042000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-15082000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
35000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12732000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7722000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
829000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11992240
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10967750
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
339000
CY2019Q3 us-gaap Assets
Assets
91792000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2123000
CY2019Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1576000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
166722
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
141
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7694000
us-gaap Net Income Loss
NetIncomeLoss
-41568000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.06
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
13195000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
8345000
us-gaap Operating Expenses
OperatingExpenses
43290000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13195000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4906000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
15000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
472000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9077000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4801000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1443000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
174000
CY2019Q3 us-gaap Liabilities
Liabilities
10520000
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
12000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
326139000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
323279000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
31000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-244910000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
81272000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91792000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12029992
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12029992
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6000
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
cbio:ContractMember
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
cbio:ContractMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
cbio:ContractMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
cbio:ContractMember
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5575000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8345000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43290000
CY2019Q3 cbio Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
489000
CY2018Q3 cbio Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
651000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-12706000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.75
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12022620
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11942729
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-28000
CY2019Q1 cbio Stock Issued During Period From Stock Grants And Stock Options Exercised Value
StockIssuedDuringPeriodFromStockGrantsAndStockOptionsExercisedValue
106000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
129000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
44000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1569838
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
106000
us-gaap Share Based Compensation
ShareBasedCompensation
1866000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
112000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-13780000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
93111000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
801000
CY2019Q3 cbio Stock Issued During Period From Stock Grants And Stock Options Exercised Value
StockIssuedDuringPeriodFromStockGrantsAndStockOptionsExercisedValue
92000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
30774000
CY2017Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
207000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
30981000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
606000
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
106762000
CY2018Q1 cbio Stock Issued During Period Value Common Stock Upon Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponExerciseOfWarrants
9545000
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3000
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
142851000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
550000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-6482000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
136963000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
710000
us-gaap Profit Loss
ProfitLoss
-41568000
us-gaap Profit Loss
ProfitLoss
-19218000
us-gaap Share Based Compensation
ShareBasedCompensation
2533000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-116000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
477000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2429000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
875000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-378000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2944000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
234000
cbio Increase Decrease In Operating Lease Liability And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset
57000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-167000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35524000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19542000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
133967000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
60337000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
106950000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
135612000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
65000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
201000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26952000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-75476000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
5082000
cbio Proceeds From Issuance Of Common Stock For Secondary Public Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockForSecondaryPublicOfferingNetOfIssuanceCosts
106762000
cbio Proceeds From Issuance Of Common Stock From Stock Grants And Option Exercises
ProceedsFromIssuanceOfCommonStockFromStockGrantsAndOptionExercises
327000
cbio Proceeds From Issuance Of Common Stock From Stock Grants And Option Exercises
ProceedsFromIssuanceOfCommonStockFromStockGrantsAndOptionExercises
36000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9545000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
327000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
111261000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8245000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16243000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31263000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19805000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23018000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36048000
cbio Noncash Impact On Adoption Of New Accounting Principle
NoncashImpactOnAdoptionOfNewAccountingPrinciple
207000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3000
cbio Noncash Or Part Noncash Unrealized Gain Loss On Investments
NoncashOrPartNoncashUnrealizedGainLossOnInvestments
35000
cbio Noncash Or Part Noncash Unrealized Gain Loss On Investments
NoncashOrPartNoncashUnrealizedGainLossOnInvestments
-24000
cbio Non Cash Or Part Non Cash Right Of Use Asset And Operating Lease Liability Recorded Upon Adoption Net
NonCashOrPartNonCashRightOfUseAssetAndOperatingLeaseLiabilityRecordedUponAdoptionNet
2052000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35998000
CY2018Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
85000000
CY2019Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
83684000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
119053000
CY2019Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
83653000
CY2019Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
31000
CY2019Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
83684000
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
119057000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
119053000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-04-30
cbio Lessee Operating Lease Renewal Term Description
LesseeOperatingLeaseRenewalTermDescription
no stated renewal options
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M6D
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
578
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
596
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
613
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
209
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2137
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
222
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1915
us-gaap Operating Lease Payments
OperatingLeasePayments
420000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1361977
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
426500
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
41219
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
10698
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
649116
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1569838
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.04
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.00
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.57
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.27
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
92.53
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.99
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.14
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
10.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M9D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M17D
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
801000
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
13392
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1032672
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1569838
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12706000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7694000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41568000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19218000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1577695
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
106800000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
489000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
652000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1763000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1539000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-116000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1497000

Files In Submission

Name View Source Status
0001564590-19-041706-index-headers.html Edgar Link pending
0001564590-19-041706-index.html Edgar Link pending
0001564590-19-041706.txt Edgar Link pending
0001564590-19-041706-xbrl.zip Edgar Link pending
cbio-10q_20190930.htm Edgar Link pending
cbio-20190930.xml Edgar Link completed
cbio-20190930.xsd Edgar Link pending
cbio-20190930_cal.xml Edgar Link unprocessable
cbio-20190930_def.xml Edgar Link unprocessable
cbio-20190930_lab.xml Edgar Link unprocessable
cbio-20190930_pre.xml Edgar Link unprocessable
cbio-ex311_6.htm Edgar Link pending
cbio-ex312_8.htm Edgar Link pending
cbio-ex321_7.htm Edgar Link pending
cbio-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gq31n4wmxwr5000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending